• Looking into the future
  • CD28 targeting
  • How it works

Looking into the future

Beyond bispecific antibodies

There is no doubt that bispecific antibodies represent a major step forward in the development of effective therapies to treat different diseases.

Complex indications as well as emerging treats such as infectious diseases require novel approaches to multi-targeting.

We are actively developing our antibody light chain approach to create bispecific antibody mixtures in a simple and reliable manner.

If you share our vision and want to work with us, please contact us.

New publication in ImmunoTherapy of Cancer

Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies

Read more

LinkedIn